Labcorp Holdings Inc

LH: XNYS (USA)
View Stock Summary
Morningstar Rating for Stocks Fair Value Economic Moat Capital Allocation
$275.00DxtvbjPyggqycwv

LabCorp Navigates Softening Demand for COVID-19 Tests in Q1; Shares Moderately Undervalued

LabCorp posted first-quarter results that were generally consistent with our expectations, and we’re holding steady in our fair value estimate, as nothing in the quarter prompted us to materially change our underlying assumptions. We remain confident in the firm’s narrow economic moat, as LabCorp continues to benefit from its scale-derived cost advantage. Nonetheless, we expect near-term profitability to be constrained by ongoing pressure from labor and transportation costs as well as decisions about how much excess capacity to carry in the event another COVID-19 variant emerges.

Sponsor Center